In this webinar, Andrew Greenwald explores various methods for performing physical titer analysis of lentiviral vectors (LVV) via p24 capsid protein measurement.
After comparing traditional approaches with real-time and automated imaging technologies, Andrew introduced process enhancements to reduce expenses and shorten the assay duration, whilst maintaining quantitative analysis, high sensitivity, and regulatory compliance, providing advantages for both Genezen, as a CDMO, and its clients.
In this presentation, you will discover:
- Comparative data that highlights LVV physical titer analysis employing Ella™, a benchtop automated ELISA platform, and VideoDrop, a nanoparticle imaging analyzer, along with conventional manual ELISAs
- A comparison of infectious titer analysis utilizing flow cytometry, VideoDrop, and droplet digital PCR (ddPCR)
- Insights into the appropriateness of each method for smaller upstream sample runs and larger viability runs for downstream processes, including the related costs and time savings
Speaker
Andrew Greenwald
Scientist, Analytical Development Group, Genezen Laboratories
After earning a biotechnology degree from Indiana University in 2009, Andrew started his career as a laboratory technician at Dow Agrosciences. His primary focus was protein quantification, which is where he started using automated instrumentation.
Andrew then joined Labcorp Drug Development (formerly Covance) in 2017, working as a Study Coordinator and Scientific Specialist. In May 2011, he moved to Genezen Laboratories.